Blog/News

Welcome back to The Excell-ence Exclusive! Your quarterly source for expert insights into cell therapy manufacturing. In each issue, we share thought-provoking articles from the Excellos scientific team, highlighting technical expertise, indu . . .

When it comes to cell therapy, your starting material can make all the difference --- not just in outcomes, but in efficiency, reproducibility, and long-term success. At Excellos, we believe the quality and consistency of your donor material sh . . .

Proud to Be Part of ARM: Advancing the Future of Regenerative Medicine Together At Excellos, we are honored to be a member of the Alliance for Regenerative Medicine—a driving force behind the progress, innovation, and advocacy that is transforming . . .

Spotlight on Excellence: Cell Therapy Quality Assurance Team The value of a QA team at a cell therapy CDMO lies in their ability to ensure that every aspect of the development and manufacturing process is performed with the highest level of . . .

Find how you can see state-of-the-art manufacturing, why decentralized manufacturing makes sense, and why mito functions are key to selecting CAR-T donors. Excellos Newsletter Launches Focusing on Innovations in Cell Therapy Manufacturing . . .

Excellos project management team At Excellos, our success is built on the expertise and dedication of our incredible teams. In this ongoing series, we’re highlighting the people behind the innovation—showcasing the teams that make our work possi . . .

Excellos: From Blood Bank Division to Leading Cell Therapy CDMO | A Legacy of Innovation At Excellos, we are driven by a mission that seamlessly blends cutting-edge science with a legacy of service. Our journey began as a division of the San Diego . . .

This case study is available as a downloadable PDF for offline reading. . . .

What you need to know about choosing peripheral blood mononuclear cells for your research and development projects   What are PBMCs? Human peripheral blood mononuclear cells (PBMCs) are key components of the body’s immune system. PBMCs ar . . .

American Association for Cancer Research (AACR) held their 2024 annual meeting in San Diego CA. This conference served as a platform for groundbreaking advancements in allogeneic cell therapy highlighted across a range of diseases.   Safeguard . . .

Cell Therapy Supply Chain With 1920 ongoing clinical trials as of Q4 2023, the pipeline for new therapies is rich in diversity of diseases under investigation and is continuing to grow. A major follow-on question is whether the gene and cell therapy . . .

Robust pipeline demonstrated at Advanced Therapies Week 2024 As we reflect on the monumental strides made in 2023 within the field of cell and gene therapy, Advanced Therapies Week 2024 served as an inspiring launchpad for the year ahead. Groundbrea . . .

TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements EDINBURGH, Scotland, Oct. 25, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechno . . .

In a recent publication [1], a collaborative research group based in La Jolla, CA cite using Excellos sourced T cells to discover cell subset-based links to disease risk by using single-cell analysis. The La Jolla researchers are studyin . . .

Scientists at the University of Florida College of Medicine report that natural variability in donor stem cells can have a dramatic impact on the transduction efficiency of vector-delivered cell and gene therapy products. [1] Gene therap . . .

Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell immune profiling for their research on severe COVID-19. [1] The purpose of the study was to identify wh . . .

A case of immune T cell identity theft (trogocytosis) gave German scientists the vital clue they needed to understand a key mechanism behind the development of multiple sclerosis (MS). In a recently published paper, scientists at the Institute of . . .

Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient ways to screen for rare B antigen-specific B cells. [1] Today, monoclonal antibodies (mAbs) are at . . .

Researchers at UCSD and Memorial Sloan Kettering Cancer Center used Excellos healthy donor starting material to carry out a fascinating study on ultrasonic activation of cancer immunotherapy. CAR-T cell therapy is a paradigm shifting therape . . .

NK cell therapy holds the promise of new therapeutics for underserved cancer indications. A recent publication in Nature Communications uses Excellos sourced cellular starting materials for research on the mechanisms behind NK cell cytotoxicity. [1 . . .

A new Allogeneic CAR-T study has shown CAR-T cells derived from healthy donors to be superior at fighting cancer compared to CAR-T cells derived from patients. [1] In a press release, biotechnology company Allogene Therapeutics announced pre . . .

Where the Cell Therapy industry is facing an ever-growing complexity in supply chain and logistics, now is the time to optimize the cell therapy supply chain to create a dependable supply of cellular therapeutics. Adam Clark, Director of Commercial . . .

Raw material experts Dr. David Wellis and Dr. Robert Tressler want to share their knowledge on how to select and source cellular starting materials that build the foundations of successful cell therapies. Dr. Wellis and Dr. Tressler are . . .

Next-level donor immune cell characterization can be used as a foundation for promoting high patient response rates. Last week in Part 1 of our donor characterization series, we dove into T cell function and donor immune cell characterizatio . . .

Donors play an important role in how well patients respond to immunotherapy, making donor characterization a critical success factor. Chimeric antigen receptor (CAR) T cell therapy has shown very promising results, helping leukemia and lymphoma . . .

Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cel . . .

Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its r . . .

T cell immunotherapy is a promising and relatively new field of medicine focused on tailoring a person’s own immune cells to fight disease more effectively. The field has enjoyed early success in the area of cancer immunotherapy, most notably the . . .